Mitsu Chem Plast Gets BSE Nod for Rs 15.1 Crore Warrant Issue

The company will issue 10,00,000 warrants at a price of Rs 151 per warrant. These will convert into 10,00,000 equity shares of Rs 10 face value each.

Reader Takeaway: The issuance brings fresh capital for Mitsu Chem Plast while imposing strict trading discipline on the allottees.

What just happened

Mitsu Chem Plast has received in-principle approval from BSE Limited for a preferential issue of 10 lakh warrants. The warrants are being issued to a mix of promoters and non-promoters. The floor price for this issuance is set at Rs 151 per warrant, representing the company's valuation benchmark for this capital infusion.

Why this matters

This approval marks a significant step for the company in its fundraising efforts. By opting for a preferential issue of warrants, Mitsu Chem Plast is looking to shore up its equity base. For existing shareholders, this means a potential dilution of equity once these warrants are converted into fully paid-up shares, but it also indicates the company's ability to raise capital from specific investors.

Regulatory Conditions and Compliance

The BSE approval is not unconditional. The exchange has laid out a stringent framework that the company must follow:

• Monitoring Trades: The company must establish robust internal controls to keep a watch on the trading activities of the proposed allottees regarding the company’s stock.
• No Intra-day Trading: Allottees must provide an undertaking that they will refrain from intra-day trading or selling any existing company shares until the final allotment of these new securities is completed.
• Regulatory Adherence: The company is required to strictly follow the Companies Act, 2013, and SEBI (ICDR) Regulations, 2018. Specifically, the management must verify compliance with Regulation 167(6).
• Listing Obligations: Upon allotment, the company must file its listing application within 20 days as per SEBI circulars.

Risks to watch

The exchange has made it clear that any failure to adhere to these mandates or the discovery of false information will result in the immediate withdrawal of the in-principle approval. Investors should monitor the company’s follow-up filings to ensure these conditions are met without hitches.